Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

Core Insights - Knight Therapeutics Inc. has relaunched MYFEMBREE, a treatment for uterine fibroids and endometriosis, in Canada, enhancing its women's health portfolio [1][4]. Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [7]. Product Details - MYFEMBREE is a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, approved by Health Canada in September 2023, and is the first oral prescription treatment for managing heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis in pre-menopausal women [3][4]. - The total sales for gonadotropin-releasing hormone receptor (GnRH) agonist and antagonist products for endometriosis and uterine fibroids in Canada are estimated at $45 million, with a five-year CAGR of 8% [3]. Market Context - Uterine fibroids affect 20-30% of women of reproductive age, with 70-80% detected by age 50, often leading to symptoms like heavy menstrual bleeding and pelvic pain [5]. - Endometriosis affects approximately 10% of reproductive-aged women globally, with significant diagnostic delays and limited treatment options available [6].